XML 54 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Summary of Domestic and Foreign Components of Loss Before Income Taxes
The domestic and foreign components of loss before income taxes were as follows (in thousands):
Year Ended December 31,
202020192018
Domestic$(126,624)$(77,354)$(65,695)
Foreign5,847 (18,065)(3,194)
Loss before income taxes$(120,777)$(95,419)$(68,889)
Summary of Benefit for Income Taxes
The income tax expense consisted of the following (in thousands):
Year Ended December 31,
202020192018
Income tax expense:
Current:
Federal$— $— $— 
State133 — — 
Foreign686 — — 
Subtotal819 — — 
Deferred:
Federal— — — 
State— — — 
Foreign(474)— — 
Subtotal(474)— — 
Income tax expense$345 $— $— 
Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate
The difference between the income tax expense and the amount computed by applying the federal statutory income tax rate to loss before income taxes is explained as follows (in thousands):
Year Ended December 31,
202020192018
Tax at federal statutory rate$(25,363)$(20,038)$(14,467)
State taxes, net(3,168)(9,597)(2,849)
Foreign rate differential376 (665)(177)
Global Intangible Low-Taxed Income1,335 — — 
Non-deductible stock-based compensation4,232 2,817 (2,729)
Research credits(3,657)(3,429)(1,005)
Change in valuation allowance26,537 29,655 20,271 
Other53 1,257 956 
Income tax expense$345 $— $— 
In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. The Company does not expect any significant benefit to its income tax provision as a result of this legislation.
Schedule of Company's Deferred Tax Assets Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):
December 31,
20202019
Assets:
Deferred tax assets:
Net operating loss carryforwards$164,276 $133,765 
Research and development tax credit carryforwards27,679 21,459 
Stock-based compensation5,321 4,194 
Deferred revenue20,681 32,171 
Fixed assets10,525 11,282 
Lease liability10,251 11,722 
Accruals and reserves430 675 
Other308 151 
Total deferred tax asset239,471 215,419 
Valuation allowance214,351 187,724 
Deferred tax assets25,120 27,695 
Liabilities:
Intangible assets(14,321)(13,609)
Operating lease right-of-use assets(17,510)(20,656)
Deferred tax liabilities(31,831)(34,265)
Total net deferred tax liabilities$(6,711)$(6,570)
The deferred tax assets and liabilities based on tax jurisdictions are presented on the Consolidated Balance Sheet as follows (in thousands):
December 31,
20202019
Deferred tax assets (included in Other non-current assets on the Consolidated Balance Sheet)$474 $— 
Deferred tax liabilities(7,185)(6,570)
Net deferred tax liabilities$(6,711)$(6,570)
Summary of Activity Related to Company's Unrecognized Tax Benefits
The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands):
December 31,
202020192018
Beginning balance$11,630 $6,288 $5,659 
Additions based on tax positions related to the current year2,834 5,393 636 
Additions for tax positions of prior years1,982 — — 
Reductions for tax positions of prior years(3,554)(51)(7)
Ending balance$12,892 $11,630 $6,288